R. John Fletcher

Chairman of the Board

R. John Fletcher has served on the Board of Directors since March 2002. Mr. Fletcher is currently Chief Executive Officer of Fletcher Spaght, Inc. (FSI), a strategy consulting organization, which he founded in 1983, and Managing Director of Fletcher Spaght Ventures, a venture fund. Prior to FSI, Mr. Fletcher was a manager at the Boston Consulting Group. He has an MA in Finance from the Wharton School, University of Pennsylvania and an MBA from Southern Illinois University. Mr. Fletcher is a director of AutoImmune, Inc., a public biotechnology company developing orally administered pharmaceutical products; Axrelis Technologies, a semiconductor equipment company; and Panacos Pharmaceuticals Inc., a biotechnology company focused on therapeutic solutions for infectious disease.

Anne Melissa Dowling, CFA

Director

Ms. Dowling joined the board in 2009 and is the Deputy Commissioner of Insurance for the State of Connecticut.  Prior to that she was at MassMutual and was the Senior Vice President for Strategy of the US Insurance Group at MassMutual Financial Group (MMFG) during 2006 and 2007. In this role she determined the strategy for the insurance businesses (individual life, institutional insurance, disability income, long-term health care, structured settlements), identifying new markets for MassMutual to pursue, new businesses to enter and disposition of non-strategic businesses. From 1996 to 2006, she built the Large Corporate Markets Division, which served professional groups, employers and high net worth individuals and families with executive benefit program design, balance sheet management, benefit funding and advanced estate planning tools. Prior to the merger of MassMutual with Connecticut Mutual (CML) in 1996, Anne Melissa was the Chief Investment Officer at CML, where she was also responsible for the variable products lines: annuities, mutual funds and qualified pension products. She came to CML from Travelers, where she had established the International Investment department and was one of the two insurance General Account managers responsible for the top-down investment policy of these portfolios. Ms. Dowling is a Chartered Financial Analyst (CFA) and graduated from Columbia University School of Business with an MBA in Finance and from Amherst College with a dual degree in Fine Arts and French. She is currently a member of the boards of Miss Porter’s School and the Hartford Public Library and has served as a trustee of Amherst College, University of Connecticut Foundation and numerous other community organizations.

Scott Drake

Director

Scott Drake joined Spectranetics as the Chief Executive Officer in August 2011. Prior to joining Spectranetics Scott held the position of Senior Vice President, Operations of DaVita, Inc. (NYSE: DVA), a leading U.S. provider of kidney care and dialysis. At DaVita, he had responsibility for business operations that generated approximately 20% of the company’s revenue, which exceeds $6 billion. Previously, Mr. Drake held several positions of increasing responsibility within various healthcare business units at Covidien, Plc over a period of 17 years. From 2006 to 2009, Mr. Drake was Global Business Unit President, Respiratory and Monitoring Solutions, a $1.5 billion business with 8,000 employees. Under his leadership, significant operational improvements were made, including revenue and profit growth; enhanced new product development pipeline; lifting of FDA consent decree; and lean six sigma operational excellence initiatives. Foundational to these accomplishments is an intense focus on new product development, organizational effectiveness and customer needs. From 2003 to 2006, he was President, Valleylab (recently re-named Energy-Based Devices), a $375 million surgical device business, where organic revenue growth accelerated from 4% to 24% during his tenure. From 2001 to 2003, he was Vice President and General Manager, Critical Care, a $150 million business unit where revenue growth and operating profitability improved under his leadership. Prior to 2001, Mr. Drake held several positions in sales and marketing management within various medical device business units. Mr. Drake holds a B.S. in business administration from Miami University of Ohio.

William C. Jennings

Director

Mr. Jennings retired from PricewaterhouseCoopers, one of the largest accounting firms in the world, in 1999, where he served over 28 years, including two separate periods covering 21 years as a senior audit partner serving several of the firm’s largest accounts and seven years developing and leading a risk management and internal control consulting practice. From 1985 to 1991, Mr. Jennings also held a senior administrative executive position at Shearson Lehman Brothers and served as chief financial officer at Bankers Trust Company. Mr. Jennings graduated with a Bachelor of Science degree from the University of Akron and also holds a Master of Business Administration degree from the University of Florida. He joined the board in 2009 and also serves on the boards of Silgan Holdings Inc., a leading manufacturer of consumer goods packaging products, and Axcelis Technologies, Inc., a leading provider of equipment and service for the semiconductor equipment industry.

B. Kristine Johnson

Director

B. Kristine Johnson is President of Affinity Capital Management, a venture capital firm that invests in private, U.S. based healthcare companies. She has held this position since 2000. Prior to joining Affinity Capital Management in 1999, she was Senior Vice President and Chief Administrative Officer of Medtronic, Inc. During her 17 years at Medtronic, she also served as President and General Manager of its vascular business and President and General Manager of its tachyarrhythmia management business. Ms. Johnson received her B.A. from St. Olaf College. She currently serves on the Board of Directors of Piper Jaffray, a leading middle market investment bank and asset management firm. She also serves on the Boards of Directors of St. Olaf College, the University of Minnesota Foundation and the University of Minnesota Physicians as well as the boards of several private entities.

Daniel A. Pelak

Director

Mr. Pelak is Senior Advisor at Welsh, Carson, Anderson & Stowe. He has over twenty years of experience as a senior executive in the medical technology industry. Mr. Pelak was previously the Chief Executive Officer at InnerPulse, Inc., a privately held, early-stage cardiac medical device company. Before joining InnerPulse, he was the Chief Executive Officer of Closure Medical Corporation, a publicly traded global leader in the development and manufacture of biomaterial-based medical adhesives, until its acquisition by Johnson & Johnson in 2005. He began his industry career at Medtronic, Inc., where he spent more than two decades. His executive assignments there included Vice President of U.S. marketing, and, later in his career, the worldwide responsibility for three different operating divisions as the Vice President and General Manager. Mr. Pelak is currently the Chairman of K2M, Inc., and also serves on the board of the directors of the following corporations: Affinergy, Inc., InnerPulse, Inc., Vertos Medical Corp., and Mardil, Inc.

Joseph M. Ruggio, M.D.

Director

Joseph M. Ruggio, M.D., has served as a director of the Company since February 1997. Dr. Ruggio is a practicing interventional cardiologist. Since June 1994, Dr. Ruggio has served as President and Chief Executive Officer of Pacific Cardiovascular Associates Medical Group, Inc., a large cardiovascular professional corporation. He also serves as Chairman and President of Via Vitae, a cardiovascular disease management company, which was founded in February 1996. Prior to that, Dr. Ruggio served as founder and Chairman of UltiMed, Inc., a cardiovascular medical services organization, which was founded in July 1995. From August 1985 to December 1995, he served as Chairman of the Department of Cardiology and Director of Invasive Interventional Cardiology for FHP, Inc. Dr. Ruggio serves on several committees of the American College of Cardiology as well as several medical advisory boards.

Maria Sainz

Director

Maria Sainz was appointed to the Board of Directors in 2010. Ms. Sainz has served as the President and CEO at Cardiokinetix, Inc since February 2013.  From April 2008 through February 2013, Ms. Sainz has served as President, CEO, and as a member of the board of directors of Concentric. From February 2003 through July 2006, Ms. Sainz served as President of the Cardiac Surgery division of Guidant Corporation. From January 2001 through February 2003, Ms. Sainz served as Vice President, Global Marketing for the Vascular Intervention division of Guidant Corporation. From late 1998 through early 2001, Ms. Sainz served as Vice President of the Intermedics Cardiac Rhythm Management business of Guidant Corporation in Europe after the acquisition of Intermedics by Guidant. Prior to that Ms. Sainz held several sales and marketing assignments of increasing responsibility in Guidant’s European operations. Ms. Sainz received an M.A. in Languages from the University Complutense in Madrid, Spain and a Masters in International Management from the American Graduate School of International Management.